- Home
- KOPN vs CUE Comparison
KOPN vs CUE Comparison
Compare KOPN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOPN
- CUE
- Stock Information
- Founded
- KOPN 1984
- CUE 2014
- Country
- KOPN United States
- CUE United States
- Employees
- KOPN N/A
- CUE N/A
- Industry
- KOPN Semiconductors
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- KOPN Technology
- CUE Health Care
- Exchange
- KOPN Nasdaq
- CUE Nasdaq
- Market Cap
- KOPN 255.1M
- CUE 48.0M
- IPO Year
- KOPN 1992
- CUE 2018
- Fundamental
- Price
- KOPN $1.58
- CUE $0.68
- Analyst Decision
- KOPN Strong Buy
- CUE Strong Buy
- Analyst Count
- KOPN 3
- CUE 3
- Target Price
- KOPN $2.58
- CUE $3.00
- AVG Volume (30 Days)
- KOPN 3.1M
- CUE 313.6K
- Earning Date
- KOPN 08-07-2025
- CUE 08-13-2025
- Dividend Yield
- KOPN N/A
- CUE N/A
- EPS Growth
- KOPN N/A
- CUE N/A
- EPS
- KOPN N/A
- CUE N/A
- Revenue
- KOPN $50,841,018.00
- CUE $7,991,000.00
- Revenue This Year
- KOPN $8.02
- CUE N/A
- Revenue Next Year
- KOPN $20.99
- CUE $23.84
- P/E Ratio
- KOPN N/A
- CUE N/A
- Revenue Growth
- KOPN 28.16
- CUE 13.83
- 52 Week Low
- KOPN $0.56
- CUE $0.45
- 52 Week High
- KOPN $2.17
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- KOPN 55.40
- CUE 47.91
- Support Level
- KOPN $1.44
- CUE $0.65
- Resistance Level
- KOPN $1.64
- CUE $0.71
- Average True Range (ATR)
- KOPN 0.09
- CUE 0.08
- MACD
- KOPN -0.02
- CUE 0.00
- Stochastic Oscillator
- KOPN 53.85
- CUE 38.62
About KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.